FDA Approved: BOSULIF — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

View source ↗

Summary

FDA approved a supplemental NDA for Bosulif (bosutinib) from Pfizer Laboratories Div Pfizer Inc, resulting in an approved change to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• BOSULIF (bosutinib)

Snippet

SUPPL AP for BOSULIF (BOSUTINIB)